Lv11
30 积分 2025-07-12 加入
Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and cons
2小时前
待确认
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
2个月前
已完结
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
2个月前
已完结
Clinical Trial Landscape in NASH
2个月前
已完结
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease
2个月前
已完结
The impact of chiglitazar, a pan-PPAR agonist, on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: a real-world study
2个月前
已完结
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
2个月前
已完结
Metabolic dysfunction-associated steatotic liver disease in adults
2个月前
已完结
Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?
3个月前
已完结
Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH
3个月前
已完结
皖公网安备34019202002308
